Expert Review Of Pharmacoeconomics & Outcomes Research

SCI SCIE SSCI

国际简称：EXPERT REV PHARM OUT 参考译名：药物经济学和结果研究专家评论

主要研究方向：HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY 非预警期刊审稿周期：较慢,6-12周

《药物经济学和结果研究专家评论》(Expert Review Of Pharmacoeconomics & Outcomes Research)是一本由Taylor and Francis Ltd.出版的以HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q3 JCR分区
121 年发文量
2.2 IF影响因子
未开放 是否OA
41 H-index
2001 创刊年份
6 issues/year 出版周期
English 出版语言

Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.

The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results

Article Highlights – an executive summary of the author’s most critical points.

[ 查看全部 ]

投稿咨询加急咨询

Expert Review Of Pharmacoeconomics & Outcomes Research期刊信息

ISSN：1473-7167
出版语言：English
是否OA：未开放
E-ISSN：1744-8379
出版地区：ENGLAND
是否预警：否
出版商：Taylor and Francis Ltd.
出版周期：6 issues/year
创刊时间：2001
开源占比：0.2018
Gold OA文章占比：11.59%
OA被引用占比：0.0824...
出版国人文章占比：0.02
出版撤稿占比：0
研究类文章占比：71.07%

Expert Review Of Pharmacoeconomics & Outcomes Research CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

3.4

0.511

0.658

学科类别	分区	排名	百分位
大类：Medicine 小类：Health Policy	Q2	142 / 330	57%
大类：Medicine 小类：Pharmacology (medical)	Q3	154 / 278	44%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Expert Review Of Pharmacoeconomics & Outcomes Research中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	HEALTH CARE SCIENCES & SERVICES 卫生保健与服务 HEALTH POLICY & SERVICES 卫生政策与服务 PHARMACOLOGY & PHARMACY 药学	4区 4区 4区

Expert Review Of Pharmacoeconomics & Outcomes Research JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEALTH CARE SCIENCES & SERVICES	SCIE	Q3	111 / 194	43
学科：HEALTH POLICY & SERVICES	SSCI	Q3	67 / 125	46.8
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	231 / 356	35.3
学科：HEALTH CARE SCIENCES & SERVICES	SCIE	Q3	141 / 194	27.58
学科：HEALTH POLICY & SERVICES	SSCI	Q4	100 / 125	20.4
学科：PHARMACOLOGY & PHARMACY	SCIE	Q3	227 / 356	36.38

Expert Review Of Pharmacoeconomics & Outcomes Research历年数据统计

影响因子

中科院分区

Expert Review Of Pharmacoeconomics & Outcomes Research中国学者发文选摘

1、Physicians' preferences for direct-acting antivirals in the treatment of chronic hepatitis C: evidence from a discrete choice experiment in Chin
Author: Li, Yan; Du, Junni; Tian, Chenhui; Ma, Aixia; Tao, Tiantian; Chen, Pingyu

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2650162
2、Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cance
Author: Kou, Conghui; Wu, Huina; Liu, Lihui; Zhao, Xifeng; Nie, Jing

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2026.2626573
3、Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cance
Author: Liu, Tong; Yao, Yao; Liu, Bingjie; Teng, Xue; Dong, Mei; Zhang, Xin

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2509706
4、Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the US
Author: Liu, Tong; Yao, Yao; Teng, Xue; Tong, Zhiqiang; Dong, Mei; Yao, Ruihong

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521444
5、Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12
Author: Yao, Ruihong; Yao, Yao; Teng, Xue; Jin, Yao; Guan, Shangwei; Dong, Mei; Liu, Tong

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2521439
6、Cost-effectiveness analysis of Risdiplam and Nusinersen for the treatment of Chinese patients with spinal muscular atroph
Author: Huang, Yueyang; Yuan, Hongmei; Huang, Zhe

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2499720
7、Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in Chin
Author: Gan, Lei; He, Xiaoning; Wu, Jing

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2507425
8、Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in Chin
Author: Zhao, Shan; Kang, Shuo

Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14737167.2025.2483423